Display options
Cite
Labaf A, Carlwe M, Svensson PJ. Efficacy and safety of novel oral anticoagulants in clinical practice: a report from three centers in Sweden. Thromb J. 2014;12(1):29doi: 10.1186/s12959-014-0029-6.
Labaf, A., Carlwe, M., & Svensson, P. J. (2014). Efficacy and safety of novel oral anticoagulants in clinical practice: a report from three centers in Sweden. Thrombosis journal, 12(1), 29. https://doi.org/10.1186/s12959-014-0029-6
Labaf, Ashkan, et al. "Efficacy and safety of novel oral anticoagulants in clinical practice: a report from three centers in Sweden." Thrombosis journal vol. 12,1 (2014): 29. doi: https://doi.org/10.1186/s12959-014-0029-6
Labaf A, Carlwe M, Svensson PJ. Efficacy and safety of novel oral anticoagulants in clinical practice: a report from three centers in Sweden. Thromb J. 2014 Dec 02;12(1):29. doi: 10.1186/s12959-014-0029-6. eCollection 2014. PMID: 25506268; PMCID: PMC4265344.
Copy Download .nbib Format: NLM
Share it on

Thromb J. 2014 Dec 02;12(1):29. doi: 10.1186/s12959-014-0029-6. eCollection 2014.

Efficacy and safety of novel oral anticoagulants in clinical practice: a report from three centers in Sweden.

Thrombosis journal

Ashkan Labaf, Martin Carlwe, Peter J Svensson

Affiliations

  1. Department of Clinical Sciences, Lund University, Malmö, Sweden.
  2. Department of Cardiology, Skåne University Hospital, Malmö, Sweden.
  3. Department of Medicine, Hallands Hospital, Halmstad, Sweden.
  4. Department of Coagulation disorders, Skåne University Hospital, 205 02 Malmö, Sweden.

PMID: 25506268 PMCID: PMC4265344 DOI: 10.1186/s12959-014-0029-6

Abstract

INTRODUCTION: In clinical trials new oral anticoagulants (NOAC) have proved to be as effective as warfarin for thromboprophylaxis in atrial fibrillation. The aim of this study was to evaluate the efficacy and safety of these drugs in clinical practise.

METHODS AND RESULTS: All patients treated with new oral anticoagulants at Skåne University hospital and Halland County Hospital Halmstad between 2009 and September 2013 was identified in the Swedish national quality registry for atrial fibrillation and anticoagulation (AuriculA). Medical records were reviewed to identify thromboembolism and major bleeding and compared to a warfarin cohort with a time in therapeutic range (TTR) of 76%. There were 826 patients, mean age 70.6, follow up 591 years, with atrial fibrillation treated with NOAC. Dabigatran was the initial drug in 79% of the cohort. The incidences of ischemic stroke/ TIA and major bleeding were 1.9 (95% CI; 1.0-3.2) and 2.0 (95% CI; 1.1-3.5) per 100 patient-years respectively. The corresponding incidences for warfarin were 1.5 (95% CI; 1.0-2.2) and 2.5 (95% CI; 1.8-3.3), with no statistical significance between the groups. Two subdural hematomas occurred 0.4 (95% CI; 0.06-1.1) per 100 patient-years. Mean age of patients with complications was 77.9 (±5.9) and 69.3 (±11.3) for those without (p < 0.001). The discontinuation rate was 6.5% and 1.7% was due to dyspepsia for dabigatran, lower than the RE-LY trial.

CONCLUSION: This study, largely based on dabigatran shows that treatment is efficient and safe in everyday clinical practice and not significantly different compared to a warfarin cohort with tight anticoagulation control.

Keywords: Atrial fibrillation; Dabigatran; Major bleeding; Novel oral anticoagulants; Thromboembolism

References

  1. J Thromb Thrombolysis. 2014 Jul;38(1):39-44 - PubMed
  2. Drug Saf. 2006;29(5):385-96 - PubMed
  3. Eur Heart J. 2011 Sep;32(18):2282-9 - PubMed
  4. Eur Heart J. 2012 Oct;33(20):2506-7 - PubMed
  5. Circulation. 2011 May 31;123(21):2363-72 - PubMed
  6. Drugs. 2012 Sep 10;72(13):1739-53 - PubMed
  7. J Am Coll Cardiol. 2013 Jun 4;61(22):2264-73 - PubMed
  8. BMJ Open. 2013 May 03;3(5):null - PubMed
  9. N Engl J Med. 2009 Sep 17;361(12):1139-51 - PubMed
  10. J Thromb Haemost. 2005 Apr;3(4):692-4 - PubMed
  11. Eur Heart J. 2012 Nov;33(21):2719-47 - PubMed
  12. N Engl J Med. 2011 Sep 15;365(11):981-92 - PubMed
  13. N Engl J Med. 2011 Sep 8;365(10):883-91 - PubMed
  14. Scand J Clin Lab Invest. 2011 May;71(3):232-9 - PubMed
  15. Lancet. 2010 Sep 18;376(9745):975-83 - PubMed

Publication Types